Skip to main content

Marte Schrumpf Heiberg

Senior researcher
https://orcid.org/0000-0003-1104-7755
View Google Scholar profile
See publications in PubMed

Education

  • Medical Doctor (MD), University of Oslo (2001)
  • Specialist in Rheumatology (2015)
  • Doctorate (PhD) at the Department of Clinical Medicine, University of Oslo (2009)

Position

  • Senior Researcher, Department of Rheumatology, Outpatient Clinic and Research, Diakonhjemmet Hospital
  • Senior Consultant in Rheumatology, Clinic for Rheumatology, Outpatient Clinic and Research, Diakonhjemmet Hospital

Field of interest

  • Rheumatology
  • Arthritic diseases
  • Immunotherapy
  • Anti-rheumatic disease-modifying drugs

Other

  • Head of the National Clinical Network in REMEDY

Email

This email address is protected from spambots. You need JavaScript enabled to view it.

Telephone

Visiting address

Diakonhjemmet Hospital
Superintendent's residence
Reidar Kobros vei 8
0370 Oslo

Postal address

Diakohjemmet Hospital
PO Box 23 Vinderen
0319 Oslo

Projects

WP1 - Optimized medical interventions

NORTH STAR

The Nordic study of strategy trials and registries for rheumatic diseases

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercise ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP2 - PPhenotyping for personalized medicine

RIMRA

Rheumatic immune-related adverse events in patients treated with immunotherapy

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercise ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP2 - PPhenotyping for personalized medicine

START

Early diagnosis of newly occurring arthritis

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercise ullamco laboris nisi ut aliquip ex ea commodo consequat.

Publications

Publications retrieved from the National Science Archives (NVA):

Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm

2025

Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritis

2025

Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort

2025

Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study

2024

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomized controlled trial

2024

Circulating Baseline CXCR3+Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis

2024

Impaired coagulation parameters in early RA are restored by effective antirheumatic therapy: a prospective pilot study

2024

Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial

2023

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomized controlled NORD-STAR trial

2023

Rheumatology congresses post COVID-19: we cannot regress

2023

Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomized controlled trial

2022

Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis

2021

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.

2021

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial

2020

Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International Immunocancer Registry (ICIR)

2019

Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: Study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study

2017

Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study

2014

The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study

2014

Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study

2013

Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria

2012

Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis

2010